Subcutaneous ICD treats fibrillation as effectively as traditional devices - studies
This article was originally published in Clinica
Cameron Health's entirely subcutaneous implantable cardioverter-defibrillator (ICD) – said to be the first of its kind – can detect and treat ventricular fibrillation, two trials have shown. The lead UK investigator of the two company-sponsored trials, Dr Andrew Grace, of the University of Cambridge, called the S-ICD an "enormous" leap forward compared to conventional devices.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.